



(51) International Patent Classification:

C07F 9/6558 (2006.01) A61P 35/00 (2006.01)
A61K 31/675 (2006.01)

(21) International Application Number:

PCT/GB2012/050457

(22) International Filing Date:

29 February 2012 (29.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1103582.1 1 March 2011 (01.03.2011) GB
1105660.3 1 April 2011 (01.04.2011) GB

(71) Applicant (for all designated States except US): **NUCANA BIOMED LIMITED** [GB/GB]; Bassett House, 5 Southwell Park Road, Camberley, Surrey GU15 3PU (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MCGUIGAN, Christopher** [GB/GB]; 2 Alfreda Road, Whitchurch, Cardiff C14 2EH (GB). **BALZARINI, Jan** [BE/BE];

Kapeldreef 20, B-3001 Heverlee (BE). **SLUSARCYZK, Magdalena** [PL/GB]; 2 Lydstep House, Bishops Close, Whitchurch, Cardiff CF14 1PE (GB). **GONCZY, Blanka** [HU/GB]; 34 Llantrisant Street, Cathays, Cardiff CF24 4JE (GB). **MURZIANI, Paola** [IT/GB]; 42 Beatty Avenue, Cardiff CF23 5QU (GB).

(74) Agents: **HOWARD, Paul Nicholas** et al.; Carpmals & Ransford, One Southampton Row, London WC1B 5HA (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]


(54) Title: PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER

FIG. 2(B)

Human TP



(57) Abstract: Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with mycoplasma-infected cells and/or with cells with a raised level of thymidylate synthase.





(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS,

SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*